UroGen Pharma
UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies. With a portfolio fueled by ongoing innovation, we have redefined options for patients.
UroGen Pharma logo in transparent PNG and vectorized SVG …
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
UroGen Pharma | Media
UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.
UroGen Pharma
UroGen is at the forefront of what we see as a transformative shift in urothelial and specialty cancers to treat patients by nonsurgical means. This paradigm shift was demonstrated with the launch of our first commercial product in 2020: JELMYTO ® (mitomycin) for pyelocalyceal solution, the first and only FDA-approved nonsurgical treatment of ...
Brandfetch | UroGen Pharma Logos & Brand Assets
Find the UroGen Pharma style guide with brand assets such as logos, colors, fonts, and more.
UroGen Pharma | Media
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel ® , a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic ...
UroGen Pharma Ltd. (URGN) - Yahoo Finance
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary...
UroGen Pharma - LinkedIn
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our...
UroGen Pharma, Ltd. -- 3/8/2022 | TD Cowen
2022年3月8日 · UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve ...
UroGen Pharma Ltd. - AnnualReports.com
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles ...
- 某些结果已被删除